Trial Profile
A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Clazakizumab (Primary)
- Indications Cachexia; Fatigue
- Focus Adverse reactions
- Sponsors Alder Biopharmaceuticals
- 05 Nov 2010 New trial record.